Cefpodoxime + Clavulanic Acid
Cephalosporin · Antibiotic
Also known as Macpod CV, Cepodem CV, Swich CV, Monocef O CV, Zedocef CV
- ONSET
- 1.5h · Relatively rapid, typically within 1-2 hours of oral administration.
- PEAK
- 2.5h · Cefpodoxime: Approximately 2-3 hours after oral dose; Clavulanic Acid: Approximately 1 hour after oral dose.
- t½
- 2.5h · Cefpodoxime: Approximately 2-3 hours; Clavulanic Acid: Approximately 1 hour.
- DURATION
- 12h · Effective concentrations typically maintained for 12 hours with twice-daily dosing.
Mechanism
Cefpodoxime, a third-generation cephalosporin, exerts bactericidal action by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). Clavulanic acid, a beta-lactamase inhibitor, protects cefpodoxime from degradation by a wide range of beta-lactamase enzymes produced by many Gram-positive and Gram-negative bacteria. This combination synergistically extends the antimicrobial spectrum of cefpodoxime against resistant bacterial strains. Combination rationale: This FDC is rational because clavulanic acid protects cefpodoxime from enzymatic degradation by beta-lactamase-producing bacteria. This extends cefpodoxime's spectrum of activity to include many organisms that would otherwise be resistant, thereby improving its clinical utility in treating a broader range of bacterial infections.
Indications
Dosing
- Adult
- Typically 200 mg Cefpodoxime + 125 mg Clavulanic Acid orally twice daily for 5-10 days, depending on the severity and type of infection. Available strengths commonly include 200 mg + 125 mg and 100 mg + 62.5 mg tablets.
- Pediatric
- For children (typically > 3 months of age), dosing is based on the cefpodoxime component: 10 mg/kg/day in two divided doses every 12 hours, for 5-10 days. Common strengths include oral suspensions of 50 mg + 31.25 mg per 5 mL.
- Renal adjustment
- For creatinine clearance (CrCl) 30-80 mL/min: typically 200 mg Cefpodoxime + 125 mg Clavulanic Acid every 12 hours. For CrCl < 30 mL/min: administer every 24 hours. Hemodialysis patients: administer after dialysis.
- Hepatic adjustment
- No specific dose adjustment is generally required for patients with hepatic impairment, as cefpodoxime is primarily excreted renally and clavulanic acid is also predominantly eliminated by the kidneys.
- Geriatric
- No specific dose adjustment required based solely on age, but renal function should be assessed and dose adjusted if creatinine clearance is below 30 mL/min.
- Max dose
- The usual maximum daily dose for cefpodoxime is 400 mg/day, and for clavulanic acid, it is typically limited by the fixed combination to avoid adverse effects.
Pharmacokinetics
Contraindications
- Known hypersensitivity to cefpodoxime, clavulanic acid, or any other cephalosporin antibiotics
- History of severe hypersensitivity reactions to any other beta-lactam antibiotics (e.g., penicillins)
Side effects
- Clostridioides difficile-associated diarrhea (CDAD)
- Anaphylaxis and other severe hypersensitivity reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Hepatotoxicity
- Renal dysfunction (e.g., interstitial nephritis)
- Seizures (especially with high doses or renal impairment)
Pregnancy & lactation
B (Based on individual component data, indicating no evidence of harm in animal studies, but human data are limited.)
Both cefpodoxime and clavulanic acid are excreted in breast milk in small amounts. Generally considered compatible with breastfeeding, but caution is advised, and the infant should be monitored for potential adverse effects such as diarrhea, candidiasis, or allergic reactions.
Related guidelines
Other Cephalosporin drugs
Ask House about Cefpodoxime + Clavulanic Acid
Continue into a citation-backed clinical answer with the drug context already attached.